Novo Nordisk A/S
NVO
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $206.9B
$46.60
▼ -1.92%
P/E
11.45
Mkt Cap
$206.9B
52-Wk Range
$35.12–$64.16
52-Week Range
$35.12 - $64.16
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 14.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Market leadership in insulin and diabetes care with 100+ years of expertise
- Proprietary GLP-1 portfolio addressing obesity and cardiometabolic diseases
- Integrated delivery systems and digital health solutions enhancing patient outcomes
- Strong R&D pipeline and strategic partnerships accelerating innovation
- Global manufacturing and distribution network across 170+ countries
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Mild headwinds expected
Rising global obesity and type 2 diabetes prevalence driving demand
Value
Valued in line with Large Cap Pharma peers (1.1x).
Momentum
Strong
+8.5% over 3m
Quality
Excellent
High-growth business (84% revenue growth, 81% gross margin). Profitable with strong growth momentum.
Dividend
Solid
3.91% yield
Smart-money signal
Who's buying NVO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of $0.96 vs $0.77 consensus (+24.7% surprise). Revenue of $12.1B vs $10.9B expected (+11.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+24.7%
Revenue trend · last 8Q
—
+30%
+19%
+13%
+5%
+494%
+24%
+2%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.7B
$2.1B
$12.1B
$11.9B
$11.6B
$12.3B
$15.0B
$12.3B
Margins · last 8Q
Gross
—
Operating
—
Profit
26.7%
Wall Street consensus
4 analysts · 25% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
25%
Hold
50%
Sell
25%
Median Price Target
—
Latest: Deutsche Bank · Aug 27, 2026
vs Industry
How NVO stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related